7 DRUG INTERACTIONS

Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.

• Patients should inform their doctor of all medications.
• Interactions with nitrate drugs are dangerous.
• Always consult before combining with other medicines.

macimorelin and vardenafil both increase QTc interval. mefloquinemefloquine increases toxicity of vardenafil by QTc interval. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents. mefloquine increases toxicity of buy bayer levitra online vardenafil by QTc interval. vardenafil and milsaperidone both increase QTc interval. moxisylytevardenafil increases effects of moxisylyte by pharmacodynamic synergism.

What should I discuss with my healthcare provider before taking vardenafil?

Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates iloperidonevardenafil and iloperidone both increase QTc interval. isoflurane and vardenafil both increase QTc interval. itraconazoleitraconazole and vardenafil both increase QTc interval. itraconazole and vardenafil both increase QTc interval. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. vardenafil increases effects of moxisylyte by pharmacodynamic synergism. ondansetronondansetron and vardenafil both increase QTc interval. ondansetron and vardenafil both increase QTc interval. oxaliplatin and vardenafil both increase QTc interval. phenoxybenzaminevardenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. vardenafil increases effects of phenoxybenzamine by pharmacodynamic synergism. phentolaminevardenafil increases effects of phentolamine by pharmacodynamic synergism. vardenafil increases effects of phentolamine by pharmacodynamic synergism. prazosinvardenafil increases effects of prazosin by pharmacodynamic synergism. vardenafil increases effects of prazosin by pharmacodynamic synergism. ribociclibribociclib increases toxicity of vardenafil by QTc interval. ribociclib increases toxicity of vardenafil by QTc interval.

rifabutinrifabutin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifabutin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampinrifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. rifampin will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. sevofluranesevoflurane and vardenafil both increase QTc interval. sevoflurane and vardenafil both increase QTc interval.

Vardenafil (By mouth)

Avoid coadministration of sensitive CYP3A4 substrates with ivosidenib or replace with alternative therapies. If coadministration is unavoidable, monitor patients for loss of therapeutic effect of these drugs. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation. macimorelinmacimorelin and vardenafil both increase QTc interval. Macimorelin causes an increase of ~11 msec in the corrected QT interval. silodosinvardenafil increases effects of silodosin by pharmacodynamic synergism. vardenafil increases effects of silodosin by pharmacodynamic synergism. siponimod and vardenafil both increase QTc interval.

St John's WortSt John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• It is important to follow prescribed dosage instructions.
• Overuse can lead to adverse cardiovascular effects.
• Report any unusual symptoms to your doctor.

St John's Wort will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. terazosinvardenafil increases effects of terazosin by pharmacodynamic synergism. vardenafil increases effects of terazosin by pharmacodynamic synergism. tetrabenazinetetrabenazine and vardenafil both increase QTc interval. tetrabenazine and vardenafil both increase QTc interval. tovorafenibtovorafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

• Liquid Levitra helps men achieve and maintain erections.
• It usually starts working within 15-30 minutes.
• Dose should be guided by a healthcare provider.

Avoid coadministration of tovorafenib (a weak CYP3A4 inducer) with CYP3A substrates where minimal concentration changes may lead to serious therapeutic failures.

5.10 Combination with Other Erectile Dysfunction Therapies

clarithromycin and vardenafil both increase QTc interval. danazoldanazol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. danazol will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. doxazosinvardenafil increases effects of doxazosin by pharmacodynamic synergism. vardenafil increases effects of doxazosin by pharmacodynamic synergism.

Penile rehabilitation

entrectinib and vardenafil both increase QTc interval. eribulin and vardenafil both increase QTc interval. Avoid coadministration of fexinidazole with drugs known to block potassium channels and/or prolong QT interval. givinostatvardenafil and givinostat both increase QTc interval. If unable to avoid coadministration, obtain ECGs when initiating, during concomitant use, and as clinically indicated. If unavoidable, monitor patients for loss of efficacy unless otherwise recommended in the CYP3A4 substrate prescribing information. tovorafenib will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

2.1 General

amisulprideamisulpride and vardenafil both increase QTc interval. amisulpride and vardenafil both increase QTc interval. anagrelide and vardenafil both increase QTc interval. apalutamideapalutamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications.

Accuracy and precision

Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed. apalutamide will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. artemether and vardenafil both increase QTc interval. tucatinibtucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling. tucatinib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. vardenafil increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended. vilanterol/fluticasone furoate inhaledvardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. vardenafil increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid coadministration of ziftomenib with other drugs known to prolong the QTc interval. If unavoidable, obtain ECGs when initiating, during concomitant use, and as clinically indicated.

Vardenafil Hydrochloride Oral tablet

buprenorphine subdermal implantbuprenorphine subdermal implant and vardenafil both increase QTc interval. buprenorphine subdermal implant and vardenafil both increase QTc interval. buprenorphine transdermalbuprenorphine transdermal and vardenafil both increase QTc interval. buprenorphine transdermal and vardenafil both increase QTc interval. buprenorphine, long-acting injectionbuprenorphine, long-acting injection and vardenafil both increase QTc interval.

What is vardenafil used for?

buprenorphine, long-acting injection and vardenafil both increase QTc interval. carbamazepinecarbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. carbamazepine will decrease the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. ceritinib and vardenafil both increase QTc interval. clarithromycinclarithromycin and vardenafil both increase QTc interval. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms vardenafil and ziftomenib both increase QTc interval.

Are there OTHER USES for this medicine?

Withhold if QTc interval >500 ms or a change from baseline >60 ms. vardenafil and givinostat both increase QTc interval. hydroxychloroquine sulfate and vardenafil both increase QTc interval. idelalisibidelalisib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Idelalisib is a strong CYP3A inhibitor; avoid coadministration with sensitive CYP3A substrates idelalisib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Interrupt ziftomenib with QTc interval > 500 ms or a change from baseline is > 60 ms zotepinevardenafil increases effects of zotepine by pharmacodynamic synergism. vardenafil increases effects of zotepine by pharmacodynamic synergism. adagrasibadagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Vardenafil dose may need to be reduced if coadministered with moderate or strong CYP3A4 inhibitors adagrasib will increase the level or effect of vardenafil by affecting hepatic/intestinal enzyme CYP3A4 metabolism.

Where can I get more information?

asenapineasenapine and vardenafil both increase QTc interval. asenapine and vardenafil both increase QTc interval. asenapine transdermalasenapine transdermal and vardenafil both increase QTc interval. asenapine transdermal and vardenafil both increase QTc interval. Either increases effects of the other by Other (see comment).

Preparations of standard and sample solutions

Comment: Avoid combination; duplicate therapy is not recommended. buprenorphinebuprenorphine and vardenafil both increase QTc interval. buprenorphine and vardenafil both increase QTc interval. buprenorphine buccalbuprenorphine buccal and vardenafil both increase QTc interval. buprenorphine buccal and vardenafil both increase QTc interval.